Combination of FIN and empagliflozin at low dosages effectively reduces cardiac and renal lesions, proteinuria, BP, creatinine, uric acid and mortality. FIN reduced renal fibrosis and the renal expression of pro-fibrotic COL1A1. This evidence concerns the gene COL1A1 and renal fibrosis.